Pan-RAS inhibitors are being developed, such as RMC-6236, a RAS-GTP inhibitor, which has shown early efficacy in KRAS G12D pancreatic cancer and G12V NSCLC [114]. Here, KRAS is linked to non-small cell lung carcinoma.